Morgan Stanley analyst Terence Flynn maintained a Hold rating on Johnson & Johnson (JNJ – Research Report) today and set a price target of $176.00. The company’s shares opened today at $179.92.
According to TipRanks, Flynn is a 5-star analyst with an average return of 12.1% and a 64.62% success rate. Flynn covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Johnson & Johnson, and United Therapeutics.
Currently, the analyst consensus on Johnson & Johnson is a Moderate Buy with an average price target of $182.20.
See Insiders’ Hot Stocks on TipRanks >>
JNJ market cap is currently $467.4B and has a P/E ratio of 24.89.
Based on the recent corporate insider activity of 81 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of JNJ in relation to earlier this year. Earlier this month, McEvoy Ashley, the EVP, WW Chair, MedTech of JNJ sold 73,323.00 shares for a total of $12,865,416.35.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Johnson & Johnson provides healthcare products across three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas such as immunology, infectious diseases ad vaccines, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular, diabetes care, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.
Read More on JNJ:
- Yumanity declares special dividend related to asset sale, merger with Kineta
- J&J says won’t make offer for Horizon Therapeutics, Bloomberg reports
- Needham healthcare analyst to hold an analyst/industry conference call
- Horizon Therapeutics price target raised to $125 from $101 at Jefferies
- Johnson & Johnson price target raised to $178 from $170 at Morgan Stanley
